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Abstract
Background: Coronary artery disease (CAD) has a negative impact on exercise capacity. The aim of this study was
to determine how coronary microvascular function, glucose metabolism and body composition contribute to
exercise capacity in overweight patients with CAD and without diabetes.
Methods: Sixty-five non-diabetic, overweight patients with stable CAD, BMI 28–40 kg/m2 and left ventricular
ejection fraction (LVEF) above 35 % were recruited. A 3-hour oral glucose tolerance test was used to evaluate
glucose metabolism. Peak aerobic exercise capacity (VO2peak) was assessed by a cardiopulmonary exercise test.
Body composition was determined by whole body dual-energy X-ray absorptiometry scan and magnetic resonance
imaging. Coronary flow reserve (CFR) assessed by transthoracic Doppler echocardiography was used as a measure
of microvascular function.
Results: Median BMI was 31.3 and 72 % had impaired glucose tolerance or impaired fasting glucose. VO2peak
adjusted for fat free mass was correlated with CFR (r = 0.41, p = 0.0007), LVEF (r = 0.33, p = 0.008) and left ventricular
end-diastolic volume (EDV) (r = 0.32, p = 0.01) while it was only weakly linked to measures of glucose metabolism
and body composition. CFR, EDV and LVEF remained independent predictors of VO2peak in multivariable regression
analysis.
Conclusion: The study established CFR, EDV and LVEF as independent predictors of VO2peak in overweight CAD
patients with no or only mild functional symptoms and a LVEF > 35 %. Glucose metabolism and body composition
had minor impact on VO2peak. The findings suggest that central hemodynamic factors are important in limiting
exercise capacity in overweight non-diabetic CAD patients.
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Background
Randomized and observational studies have shown that
exercise capacity is a strong predictor of cardiovascular
prognosis. Even when fully revascularized, patients with
stable coronary artery disease (CAD) and normal left
ventricular ejection fraction (LVEF) have lower than
expected exercise capacity [1]. Patients with visceral
obesity or the metabolic syndrome also have impaired
exercise capacity [2]. The limiting factors of exercise
capacity in these clinical entities is unclear.
Reduced coronary microvascular function has emerged
as a strong predictor of poor prognosis. In patients with
CAD, in patients with diabetes [3] and in subjects with
cardiometabolic risk factors, such as hypertension [4]
and visceral obesity [5], coronary microvascular function
is impaired. Coronary microvascular dysfunction has
also been linked to impaired exercise capacity. We have
* Correspondence: andersjurs@gmail.com
1Department of Cardiology, Bispebjerg Hospital, University of Copenhagen,
Copenhagen, Denmark
Full list of author information is available at the end of the article
© 2015 Jürs et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jürs et al. BMC Cardiovascular Disorders  (2015) 15:159 
DOI 10.1186/s12872-015-0151-9
previously found that coronary flow reserve (CFR) as a
measure of coronary microvascular function is strongly
associated with exercise capacity in CAD and chronic
heart failure [6]. We have also described an association
between insulin sensitivity and CFR in heart failure pa-
tients [7]. An understanding of how these important
markers interact in explaining limitations to exercise
capacity is lacking. This study explores whether mea-
sures of glucose metabolism and body composition con-
tribute to the previously observed link between coronary
microvascular function and exercise capacity in over-
weight non-diabetic patients with CAD.
Methods
Study population
This study is based on baseline data from the random-
ized, controlled CUT-IT trial comparing the cardiovas-
cular effects of a weight loss facilitated using a low
energy diet (LED) and aerobic interval training in over-
weight non-diabetic patients with CAD. The study is in
compliance with the Declaration of Helsinki and has
been approved by the Regional Ethics Committee of the
Capital Region in Denmark (no H-4-2010-146) and the
Danish Data Protection Agency (no 2011-41-6313). The
trial is registered at clinicaltrials.gov (NCT01724567). In-
formed written consent for participation in the study
was obtained from all participants. The inclusion criteria
and study design have been published previously [8, 9].
In summary, inclusion criteria were CAD diagnosed
more than 6 months prior to inclusion, age 45 –
75 years, body mass index (BMI) 28–40 kg/m2 and no
diabetes. A subgroup of the patients (n = 30) were
included in a previously reported analyses of association
between CFR and VO2peak [6]. The present analyses
expand those results to a larger patient group and aims
at gaining mechanistic insight through including detailed
data on body composition and glucose metabolism.
Cardiopulmonary exercise test
The participants underwent a cardiopulmonary exercise
test (CPET) using an upright bicycle ergometer (Via
Sprint 150P, Ergoline, Bitz, Germany) with breath-by-
breath gas exchange measurement of oxygen consump-
tion and CO2 production (Jaeger, Masterscreen CPX,
Cardinal Health, Würzburg, Germany) at the screening
and the baseline visit. The screening visit was used to
familiarize the participant to the test and to ensure that
the optimal exercise protocol was used at baseline. The
data used in the present study is the baseline test. All
participants were encouraged to continue until exhaus-
tion and a satisfactory effort was anticipated when VO2
and/or heart rate failed to increase with further increases
in workload or peak respiratory exchange ratio (RER)
(VCO2/VO2) exceeded 1.05. VO2peak and RER were
calculated as the means of the six highest consecutive
five-second measurements before exercise termination.
VO2peak was adjusted to both total body weight
(VO2peakBW) (mL/kg body weight/min) and fat free
mass (FFM) (VO2peakFFM) (mL/kg FFM
(2/3)/min) [10].
Predicted VO2peak was calculated using the equation
for sedentary individuals as proposed by Wassermann
and Hansen [11].
Body composition
The participants’ fasting-state body mass, hip and waist
circumference were measured by standardized proce-
dures [9]. Body composition, including fat mass and
fat free mass, was assessed using whole body dual-
energy X-ray absorptiometry (DEXA) (Lunar DPX-IQ, GE
Lunar Corp, Madison, WI). The ratio of central to periph-
eral distribution of body fat was estimated by dividing the
body fat in the DXA trunk region of interest (ROI) by the
ROIs that encompass the arms, hips and legs [12]. Visceral
abdominal adipose tissue was determined by magnetic res-
onance imaging (MRI) in a subgroup (n = 37). MRI mea-
surements and analyses were performed using the Achieva
3.0 T MRI system and the Philips ViewForum workstation
(Philips Medical Systems, Best, the Netherlands) and a
sense cardiac coil. Images were obtained by a fast T1w
turbo field echo (TFE) MR sequence in the transverse plane
(TFE sequence, TFE factor = 136, TR = 10 ms, TE = 2.3 ms,
FOV= 480 mm, respiratory trigger compensation with
trigger delay of 1000 ms). A transverse slice (thickness:
10 mm) was acquired in the supine position in the middle
of the third lumbar vertebra and visceral fat was measured.
Oral glucose tolerance test
A 3 hour oral glucose tolerance test (OGTT) with meas-
urement of plasma glucose-, insulin- , and C-peptide
levels was performed. After a 10 hour overnight fast an
oral glucose load of 75 g dissolved in 300 ml water was
administered within 2 minutes. Plasma samples were
obtained at −10,0,10,20,30,45,60,75,90,105,120,150 and
180 minutes. Blood samples were immediately cooled on
ice and centrifuged for 10 minutes (3500 rpm, Universal
320R, Hettich Centrifugen, Tuttlingen, Germany). Glu-
cose analysis was performed using an YSI 2300 STAT
Plus Glucose and Lactate Analyser (YSI incorporated,
Yellow Springs, OH, USA). Enzyme-linked immunosorb-
ent assay (ELISA) was used to determine C-peptide and
insulin (pmol/l, Immulite 2000, Siemens Healthcare
Diagnostics, LA, Califonia, USA). Glycated hemoglobin
HbA1c was estimated by high performance liquid
chromatography.
Based on the OGTT the following glucose metabolic
parameters were calculated:
Fasting plasma glucose (FPG, mmol/L) and fasting
plasma insulin (FPI, pmol/L) were calculated as the
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average of plasma values at time −10 and 0 minutes.
Glucose tolerance was defined as the 2 hour plasma glu-
cose concentration (2 h-PG). The composite measure of
whole body insulin sensitivity (ISIComposite) [13] and the
homeostatis model assessment of hepatic insulin resist-
ance (HOMA-IR) [14] were determined as follows:
ISIcomposite ¼ 10:000ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
FPG  FPIð Þ  G  I 
q
HOMA−IR ¼ FPG  FPIð Þ
405
in which FPG is fasting plasma glucose (mg/dl), FPI is
fasting plasma insulin (μU/ml), G and I is mean plasma
glucose and insulin, respectively, measured during the
OGTT at 0, 30, 60, 90 and 120 minutes. 1/HOMA-IR was
used as an estimation of insulin sensitivity (ISIHOMA).
Prehepatic insulin secretion rates (ISR) (pmol/kg/min)
were calculated from plasma C-peptide concentrations
using the ISEC (Insulin SECretion) computer program
[15]. The method is based upon the assumptions that in-
sulin and C-peptide are co-secreted in equimolar amounts
by the pancreas and that C-peptide is not cleared by the
liver. β-Cell secretion in response to changes in glucose
concentration during the OGTT expresses the efficacy by
which changes in plasma glucose concentrations stimulate
insulin secretion. The relationship between plasma glu-
cose concentrations and ISR during the OGTT was
evaluated by cross-correlation analysis and the slope of
the regression lines (βtotal), which express the change in
insulin secretion per unit change in glucose concentration,
was used as a measure of β-cell responsiveness. Dispos-
ition index (Di) was calculated as a measure of β-cell func-
tion adjusted for insulin sensitivity [16]:
Di ¼ βtotal  ISIcomposite
Coronary flow reserve and echocardiography
All participants underwent a complete transthoracic
echocardiography using a Vivid E9 (GE Medical Systems,
Inc., Horten, Norway). Left ventricular end-diastolic vol-
ume (EDV), end-systolic volume (ESV) and left ventricu-
lar ejection fraction (LVEF) were calculated using the
biplane Simpson method. EDV and ESV were corrected
for body surface area using the Mosteller formula [17].
CFR was measured using a high frequency S6 transducer
(GE Medical Systems, Inc., Horten, Norway). All partici-
pants were instructed to abstain from caffeine 24 hours
prior to the examination and the use long acting
nitroglycerin was suspended for 24 hours. Starting in a
modified apical 5-chamber view, which intersected the
anterior wall, and using color Doppler with a low Nyquist
limit, the left anterior descending artery (LAD) was
located in its distal path. If unsuccessful the LAD was
located mid-distally in the interventricular sulcus using a
low short-axis view. Hyperemia was induced by infusion
of dipyridamole (0.84 mg/kg over 6-minutes) or adenosine
(0.14 mg/kg/min for 2 minutes) . CFR was calculated as
the ratio between peak coronary flow velocity at rest and
during hyperemia. We have previously reported inter and
intra-observer variability of repeated off-line CFR readings
with within-subject coefficient of variation (CV) of 5.5 %
(n = 39) and 7.5 % (n = 10), respectively [18].
Statistics
Unless stated otherwise all values are expressed as median
and interquartile range for continuous variables and as
number and percentage for categorical variables. Continu-
ous variables were compared using Student’s t-test and
differences in categorical variables were assessed by χ2
test. The Pearson product–moment correlation coefficient
was used to estimate the associations between continuous
variables and multivariable linear regression with stan-
dardized coefficients (SC) were performed to identify in-
dependent predictors of VO2peak. The multivariable
model included age and gender (fixed) and tested each co-
variate based on associations from univariate analyses as
specified below. Variables with p < 0.10 were retained in
the multivariable model. The significance level was set to
p < 0.05. All analyses were done using Stata 13.1 software
(StataCorp, College Station, TX, USA).
Results
We recruited 70 participants without significant stenosis
of the LAD. Of these 65 participants completed a satis-
factory CPET and had a successful CFR measurement.
In two patients the image quality was too poor to assess
CFR and three patients did not fulfill the criteria for a
satisfactory CPET. Patient characteristics are presented
in Table 1. Patients were primarily male and had well-
regulated blood pressures. Fifty-seven (87.7 %) partici-
pants had previously been revascularized, and none had
ischemic changes in ECG during CPET. Thirteen (20 %)
participants reported angina only during strenuous or
prolonged physical activity while the remaining participants
were asymptomatic. Median BMI was 31.3 (29.7-33.7) and
forty-seven (72 %) of the patients had prediabetes defined
as either impaired glucose tolerance (FPG < 7.0 mmol/L
and 7.8 ≤ 2hPG < 11.1 mmol/L) or impaired fasting glucose
(FPG 5.6-6.9 mmol/L).
No differences were found in patient characteristics
between patients with or without a successful CPET or
CFR measurement.
Coronary flow reserve and echocardiography
Median CFR was 2.28 (1.91-2.61) and median LVEF was
54 % (47–59). There was no significant difference in
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CFR in participants with and without an ischemic eti-
ology involving the LAD, by NYHA-class or gender.
Table 2 shows measures of echocardiography, exercise
capacity, glucose metabolism and body composition by
CFR above and below the median CFR. Patients with a
high CFR had a higher VO2peakFFM (P = 0.0008) and a
lower body fat percentage (P = 0.02). Results from
univariate regression on CFR are presented in Table 3
and confirms a strong association between CFR and
VO2peakFFM (p = 0.0007).
Insulin sensitivity, as defined by the parameters
ISIHOMA and ISIComposite showed no association with
CFR. Neither did β-cell function (βtotal), nor glucose
tolerance as defined by 2 h-PG. However, when grouping
participants by impaired coronary microvascular func-
tion (defined as CFR < 2) or not, glucose tolerance was
significantly worse in participants with impaired coronary
microvascular function (p = 0.008).
Exercise capacity
Though not significant, the patients had lower than
predicted exercise capacity with a median VO2peakbw of
21.3 mL/min/kg (17.5-25.1) and a median VO2peak % of
predicted of 93.9 % (p = 0.12). RER values indicated that
participants performed a satisfactory CPET. Table 2
compares echocardiographic measures, measures of glu-
cose metabolism and body composition across patients
with low and high exercise capacity dichotomized by
median VO2peakFFM. Patients with a higher exercise
capacity were younger, had larger left ventricular vol-
umes and better CFR (Table 2).
Measures of glucose metabolism were numerically better
in the patients with higher VO2peakFFM but only for FPG
and Hba1c did the difference reach statistical significance
(Tables 2 and 3). As expected, HOMA-IR, ISIComposite and
Di were, along with the glucose and insulin measurements
on which they were calculated, significantly correlated with
Hba1c, MCRi and visceral fat while the correlation to body
fat percentage was borderline-significant (data not shown).
In general participants with high VO2peakFFM had a lower
body fat percentage, less visceral fat and less abdominal fat
(Tables 2 and 3). Only body fat percentage reached
statistical significance; however, only 37 patients underwent
MRI.
Results of univariate linear regression analyses in
relation to VO2peakFFM are presented in Table 3.
VO2peakFFM was significantly correlated with LVEF,
CFR, EDV, and Hba1c. VO2peakBW showed similar
correlations.
Independent predictors of VO2peak were identified
using a multivariable regression model presented in
Table 4. Age and gender, which are traditional predictors
VO2peak, were included along with the significant corre-
lates from the univariate analysis presented in Table 3.
CFR, LVEF and EDV remained independent predictors of
exercise capacity while Hba1c was no longer significant.
ACE-inhibitors and beta-blockers can influence exer-
cise capacity and CFR. The distribution of these medica-
tions between participants with high and low CFR and
high and low VO2peakFFM is shown in Table 2. There
were no significant differences. Adjustment for the use
of beta-blockers and/or ACE-inhibitors did not affect
the association between CFR and VO2peakFFM.
CFR measurement is performed in the LAD. Adjust-
ment for involvement of LAD (PCI, CABG or MI) and
limiting analyses to patients with no involvement of the
Table 1 Patient characteristics. Values are median (IQ range) or
number (%)





Male Sex 54 (83.1 %)
Fat percentage (%) 34.0 (30.5–38.6)
BMI (kg/m2) 31.3 (29.7–33.7)
Prediabetes 47 (72.3 %)
Predicted VO2peak (%) 93.9 % (84.6–109.2)
VO2peakBW (ml/min/kg) 20.9 (17.3–25.1)
VO2peakFFM (ml/min/kg FFM
(2/3)) 127 (108.8–145.6)
Respiratory exchange ratio 1.19 (1.16–1.26)
ICD 2 (3.1 %)
Systolic blood pressure (mmHg) 127 (118–135)

















Atrial fibrillation 3 (4.6 %)
Left ventricular ejection fraction (%) 54 (46–59)
Ischemic etiology
























BMI Body mass index, ICD Implantable cardioverter-defibrillator, ASA acetylsalicylic
acid, ACE Angiotensin converting enzyme, PCI percutaneous coronary
intervention, CABG coronary artery bypass graft, LAD left anterior descending
artery, CCS Canadian Cardiovascular Society Functional Classification of Angina
Pectoris, NYHA New York Heart Association, VO2peakBW peak rate of oxygen
consumption per kilogram of body mass, VO2peakFFM peak rate of oxygen
consumption per kilogram of fat free body mass
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LAD did not affect estimates. Figure 1 shows scatter-
plots with linear regression lines between VO2peakFFM
and CFR and VO2peakFFM and LVEF. Results were simi-
lar when using VO2peakBW as the dependent variable.
Discussion
The present study is the first to investigate the effect of
glucose metabolism and body composition on coronary
microvascular function and exercise capacity in non-
diabetic overweight patients with CAD. Our results con-
firm a strong association between coronary microvascular
function and exercise capacity, but indicate that the role
of glucose metabolism and body composition is limited in
non-diabetic, overweight CAD patients and that the
reduced exercise capacity is primarily determined by other
parameters.
Microvascular function
Two studies found a correlation between insulin sen-
sitivity measured by the hyperinsulinemic-euglycemic
clamp technique and CFR in heart failure patients (n = 39)
[7] and in obese subjects (n = 36 ) [19], respectively. A
Table 2 Patient´s measurements divided into “low” or “high” groups according to median CFR and VO2peakFFM
Coronary flow reserve VO2PeakFFM
Low (CFR ≤ 2.28) High (CFR > 2.28) Low (VO2PeakFFM ≤ 126.5) High (VO2PeakFFM >126.5)
n = 32 n = 33 n = 32 n = 33
Patient characteristics
Age 64 (59–68) 62 (56–67) 65 (61–69) 62 (55–65)*
Male sex 26 (81.3 %) 28 (84.9 %) 24 (75.0 %) 30 (90.9 %)
CABG/PCI involving LAD 16 (50.0 %) 20 (60.0 %) 19 (59.4 %) 17 (51.5 %)
ACE–inhibitors 16 (50.0 %) 13 (39.4 %) 16 (50.0 %) 13 (39.4 %)
Beta–blockers 17 (53.1 %) 17 (51.5 %) 17 (53.1 %) 17 (51.5 %)
Echocardiography
Left ventricular ejection fraction (%) 53 (45–59) 56 (48–60) 54 (46–58) 55 (47–61)
End diastolic volume (mL/m2) 38.4 (34.4–50.5) 40.8 (34.5–47.7) 36.0 (31.3–39.6) 43.6 (39.2–54.1)*
End systolic volume (mL/m2) 17.6 (15.0–26.6) 17.7 (14.2–24.3) 16.4 (13.8–22.0) 18.5 (15.6–27.0)*
Coronary flow reserve (ratio) 1.91 (1.77–2.09) 2.62 (2.53–2.97)* 2.13 (1.87–2.55) 2.52 (2.07–2.71)*
Exercise capacity
VO2peakBW (ml/min/kg) 18.3 (16.5–21.9) 23.2 (20.5–27.3)* 17.7 (16.0–20.5) 25.1 (22.3–27.6)*
VO2peakFFM (ml/min/kg FFM
(2/3)) 116.0 (104.0–129.9) 135.5 (121.6–161.9)* 108.7 (98.4–119.6) 145.6 (133.1–162.7)*
Respiratory exchange ratio (RER) 1.21 (1.16–1.28) 1.19 (1.15–1.22) 1.21 (1.15–1.28) 1.18 (1.15–1.23)
Glucose metabolism
Insulin sensitivity (ISIcomposite) 2.21 (1.71–3.50) 2.49 (1.76–3.59) 2.28 (1.88–3.35) 2.48 (1.66–3.77)
Insulin sensitivity (ISIHOMA) 0.28 (0.19–0.46) 0.31 (0.22–0.46) 0.28 (0.19–0.45) 0.30 (0.22–0.48)
Hba1c (%) 5.9 (5.7–6.1) 5.9 (5.5–6.2) 6.1 (5.9–6.3) 5.8 (5.5–6.0)*
Fasting plasma glucose (mmol/L) 5.88 (5.31–6.33) 5.85 (5.65–6.18) 6.07 (5.70–6.33) 5.73 (5.46–6.07)*
Fasting plasma insulin (pmol/L) 100 (60–131) 88 (56–120) 94 (60–124) 93 (61–121)
Glucose tolerance (2 h-PG) (mmol/L) 7.95 (6.31–9.49) 7.37 (5.91–8.86) 8.14 (6.47–9.66) 7.17 (5.64–8.85)
Beta cell function (Btotal) (nL/kg/min) 1.90 (1.46–2.37) 1.93 (1.46–2.86) 1.85 (1.45–2.37) 1.99 (1.46–2.71)
β-cell function adjusted for insulin
sensitivity (Di)
4.89 (2.82–8.12) 5.52 (3.18–7.45) 5.48 (3.06–8.98) 4.64 (2.82–7.17)
Body composition
BMI (kg/m2) 31.1 (29.5–35.1) 31.5 (29.9–33.3) 31.0 (29.5–33.2) 31.8 (29.9–33.7)
Waist-to-hip-ratio 1.00 (0.98–1.03) 1.01 (0.97–1.04) 1.00 (0.96–1.05) 1.00 (0.97–1.03)
Body fat (%) 35.7 (32.6–41.0) 32.2 (29.1–35.7)* 34.3 (31.0–42.1) 33.4 (30.5–35.8)
Visceral fat (mm3) 293 (260–332)(n = 14) 276 (211–316)(n = 23) 293 (222–345)(n = 16) 280 (211–297)(n = 21)
Central-to-peripheral fat ratio 1.52 (1.34–1.70) 1.65 (1.39–2.05) 1.54 (1.34–1.82) 1.59 (1.39–1.89)
VO2peakFFM peak rate of oxygen consumption per kilogram of fat free body mass, CABG coronary artery bypass graft, PCI percutaneous coronary intervention,
LAD left anterior descending artery, Di disposition index, BMI Body mass index, VO2peakBW peak rate of oxygen consumption per kilogram of body mass. *p < 0.05
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study including non-diabetic women with suspected CAD
but angiographically normal coronary arteries (n = 45)
found a correlation between CFR and insulin resistance
using an OGTT [20]. In the present study insulin sen-
sitivity and appropriate β-cell function as measured by dis-
position index were congruent with higher CFR, but
associations were non-significant. This may be due to the
methods used. In the present study insulin sensitivity was
evaluated by an OGTT with 13 plasma samples obtained
over a 3 hour period. The clamp technique is considered
to be the gold standard, however, all indices from the
OGTT have been validated against the clamp technique
and are regarded as valid measures [13, 14]. Also, the oral
test may be considered more physiologic than the intra-
venous clamp technique by activating the important incre-
tin effects. However, when considering the glucose
tolerance in those 40 % of patients who by definition dis-
play impaired CFR (<2.0) they displayed a highly signifi-
cant impaired glucose tolerance compared to those 60 %
of patients with normal CFR. Thus data available from
previous studies and the present study appear slightly in-
consistent, but notably the number of studies is limited.
CFR is a measure of coronary microvascular function
and body composition has previously been linked to per-
ipheral endothelial function [21] and the endothelium-
related myocardial blood flow response as measured by
PET (n = 111) [22]. Therefore an association between
CFR and body composition could be expected. Partici-
pants with low CFR had a significantly higher body fat
percentage; however, the measures of body composition
were not associated with CFR in the regression analyses.
Only 37 participants underwent MRI and consequently
the study may have been under-powered to assess asso-
ciations between visceral fat and CFR.
Exercise capacity
The achieved respiratory exchange ratios achieved
during exercise testing indicate that all patients delivered
a satisfactory CPET. The equal median RER-values in
the groups of high and low exercise capacity further






r p-value r p-value
Age −0.13 0.30 −0.38 0.0015
Echocardiography
Left ventricular ejection fraction (%) 0.20 0.10 0.33 0.008
End diastolic volume (mL/m2) −0.06 0.61 0.32 0.01
End systolic volume (mL/m2) −0.10 0.44 0.13 0.30
Coronary flow reserve (ratio) - - 0.41 0.0007
Exercise capacity
VO2peakFFM (ml/min/kg FFM
(2/3)) 0.41 0.0007 - -
Respiratory exchange ratio (ratio) −0.17 0.17 −0.08 0.52
Glucose metabolism
Insulin sensitivity (ISIcomposite) 0.04 0.73 0.08 0.53
Insulin sensitivity (ISIHOMA) 0.06 0.65 0.16 0.18
Hba1c (%) 0.03 0.79 −0.30 0.014
Fasting plasma glucose (mmol/L) −0.06 0.64 −0.22 0.08
Fasting plasma insulin (pmol/L) −0.16 0.20 −0.10 0.46
Glucose tolerance (2 h-PG) (mmol/L) −0.20 0.09 −0.20 0.10
Beta cell function - Btotal (nL/kg/min) 0.11 0.36 −0.03 0.84
β-cell function adjusted for insulin
sensitivity (Di)
0.23 0.07 0.08 0.56
Body composition
BMI (kg/m2) −0.15 0.22 −0.05 0.67
Waist-to-hip-ratio 0.07 0.59 0.02 0.88
Body fat (%) −0.21 0.09 −0.29 0.02
Visceral fat (mm3) (n = 37) −0.22 0.17 −0.28 0.10
Central-to-peripheral fat ratio 0.13 0.30 −0.18 0.16
VO2peakFFM peak rate of oxygen consumption per kilogram of fat free body
mass, Di disposition index, BMI Body mass index
Table 4 Multivariable linear regression with VO2peak as the dependent variable
VO2peakFFM VO2peakBW
SC p-value SC p-value
Age −0.14 0.204 Age −0.08 0.370
Male sex 0.17 0.226 Male sex 0.01 0.901
Body fat % −0.01 0.951 Body fat % −0.40 0.002
Coronary flow reserve (ratio) 0.32 0.003 Coronary flow reserve (ratio) 0.29 0.002
Left ventricular ejection fraction (%) 0.37 0.001 Left ventricular ejection fraction (%) 0.32 0.001
Left ventricular end diastolic volume (mL/m2) 0.33 0.005 Left ventricular end diastolic volume (mL/m2) 0.29 0.005
Hb1ac (%) −0.18 0.075 Hb1ac (%) −0.17 0.063
SC Standardized coefficient, VO2peakFFM peak rate of oxygen consumption per kilogram of fat free body mass, VO2peakBW peak rate of oxygen consumption per
kilogram of body mass. Respectively 48 % and 59 % of the variance of VO2peakFFM and VO2peakBW was explained by the included variables
Jürs et al. BMC Cardiovascular Disorders  (2015) 15:159 Page 6 of 9
accentuate that the VO2peakFFM was not influenced by
exercise effort.
HbA1c and FPG demonstrated significant inverse asso-
ciations to VO2peakFFM and estimates of insulin sensitiv-
ity, glucose tolerance and β-cell function showed a trend
to associate to better exercise capacity. These findings are
only partly in concordance with previous studies. Studies
evaluating the correlation of exercise capacity and insulin
sensitivity using the glucose clamp technique in a healthy
population (n = 20 ) [23] and heart failure patients (n = 39
and n = 9 , respectively) [7, 24] reported an association be-
tween insulin sensitivity and VO2peak. A recent study of
170 patients with CAD and diabetes also found VO2peak
to be correlated with HOMA-IR but not with FPG or
Hba1c [25] while another study evaluating the effect of ex-
ercise training in a similar population found a correlation
between baseline FPG and Hba1c and VO2peak but not
between HOMA-IR and VO2peak [26].
Thus, our results indicate that the effect of the glucose
metabolism on coronary microvascular function is
limited and does not explain the previously observed
link between CFR and exercise capacity in CAD patients
without diabetes. In this group of patients, exercise
capacity was primarily determined by other parameters
than body composition and glucose metabolism. These
parameters included left ventricular ejection fraction and
end diastolic volume.
Although cardiac output is defined by stroke volume,
which in turn is determined by end diastolic volume and
ejection fraction, previous studies have not found this
straight-forward association. A large study investigating
the relationship in patients with a clinical indication for
exercise echocardiography, no exercise-induced myocar-
dial ischemia and LVEF > 50 % found no correlation
between LVEF and exercise capacity [27]. However,
exercise capacity was calculated from the exercise echo-
cardiography using metabolic equivalents, which is less
accurate compared to the CPET used in the present
study. Most studies in heart failure patients found little or
no association between LVEF and VO2peak [18, 28, 29]
whereas a study investigating the relationship in asymp-
tomatic CAD patients (n = 27) described a correlation
between peak LVEF and exercise capacity [30].
Like previous studies in healthy subjects [31, 32], heart
failure patients [7, 18] and CAD patients [6], we found a
strong correlation between CFR and exercise capacity. Ex-
ercise capacity is a strong prognostic marker in patients
with CAD [1] and it has been demonstrated that exercise
training can improve coronary endothelial function in
CAD patients [33]. In this study population consisting of
overweight CAD patients with a LVEF > 35 % and pri-
marily NYHA class I or II, CFR remained an independent
predictor of VO2peakFFM in the multivariable linear regres-
sion analysis alongside LVEF and EDV. This is, to our
knowledge, the largest study evaluating the correlation of
CFR and exercise capacity and the first study establishing
CFR and LVEF to be independent predictors of VO2peak.
Conclusion
The study established that coronary microvascular function
and LVEF are independent predictors of VO2peak in over-
weight CAD patients with no or only mild functional
symptoms and a LVEF > 35 %. Glucose metabolism and
body composition were weak determinants of exercise cap-
acity and did not contribute significantly to explain the link
between CFR and exercise capacity. The findings suggest
that central hemodynamic factors are important in limiting
exercise capacity in overweight non-diabetic CAD patients.
Fig. 1 Scatter plots with linear regression lines and confidence interval (CI) between VO2peakFFM and CFR (left) and VO2peakFFM and LVEF (right)
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